Reference 2019-324

REF:            2019-324

Subject:        Disodium pamidronate (Aredia)

 

 

Request:

  1. Within your health trust how many patients are, within the past 6 months that you have data available, being treated with the following treatments? This is regardless for the disease being treated.

Disodium pamidronate (Aredia)

Ibandronic acid or ibandronate (Bondronat)

Sodium clodronate (Bonefos, Clasteon, Loron)

Zoledronic acid or zoledronate (Zometa)

Denosumab (Xgeva)

Omalizumab [Xolair]

Mepolizumab [Nucala]

Reslizumab [Cinqaero]

Benralizumab [Fasenra]

 

  1. How many paediatric patients have been treated in the last 6 months with Xolair/omalizumab?

 

Response:  

The following number of patients were treated between 01/11/2018 and 30/04/2019.

Zoledronic Acid is kept as stock on Churchill Unit so we do not have any figures for patients issued with ward stock.

Disodium pamidronate (Aredia) 9
Ibandronic acid or ibandronate (Bondronat) 2
Sodium clodronate (Bonefos, Clasteon, Loron) 7
Zoledronic acid or zoledronate (Zometa) 52 (This figure does not include any patients issued with ward stock)
Denosumab (Xgeva) – 1
Omalizumab [Xolair] 13
Mepolizumab [Nucala] 0
Reslizumab [Cinqaero] 0
Benralizumab [Fasenra] 0
How many paediatric patients have been treated in the last 6 months with Xolair/omalizumab? 0